These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19132188)

  • 1. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease.
    Hurks R; Peeters W; Derksen WJ; Hellings WE; Hoefer IE; Moll FL; de Kleijn DP; Pasterkamp G
    Thromb Haemost; 2009 Jan; 101(1):48-54. PubMed ID: 19132188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New predictors of adverse cardiovascular events following vascular surgery.
    van Lammeren GW; de Vries JP; Vink A; de Kleijn DP; Moll FL; Pasterkamp G
    Semin Cardiothorac Vasc Anesth; 2010 Jun; 14(2):148-53. PubMed ID: 20478956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization.
    Hellings WE; Peeters W; Moll FL; Pasterkamp G
    Trends Cardiovasc Med; 2007 Jul; 17(5):162-71. PubMed ID: 17574124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events.
    de Kleijn DP; Moll FL; Hellings WE; Ozsarlak-Sozer G; de Bruin P; Doevendans PA; Vink A; Catanzariti LM; Schoneveld AH; Algra A; Daemen MJ; Biessen EA; de Jager W; Zhang H; de Vries JP; Falk E; Lim SK; van der Spek PJ; Sze SK; Pasterkamp G
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):612-9. PubMed ID: 20018935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vulnerable patient: refocusing on the plaque?
    Eijgelaar WJ; Heeneman S; Daemen MJ
    Thromb Haemost; 2009 Aug; 102(2):231-9. PubMed ID: 19652873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events.
    Peeters W; de Kleijn DP; Vink A; van de Weg S; Schoneveld AH; Sze SK; van der Spek PJ; de Vries JP; Moll FL; Pasterkamp G
    Eur Heart J; 2011 Jul; 32(14):1758-68. PubMed ID: 21059735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events.
    Cola C; Clementi E; Biondi-Zoccai G; Sangiorgi G
    Acta Chir Belg; 2007; 107(2):129-42. PubMed ID: 17515260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the vulnerable patient with rupture-prone plaque.
    Weintraub HS
    Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis.
    Koenig W
    Ann Med; 2009; 41(5):332-43. PubMed ID: 19291518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
    Naghavi M; Libby P; Falk E; Casscells SW; Litovsky S; Rumberger J; Badimon JJ; Stefanadis C; Moreno P; Pasterkamp G; Fayad Z; Stone PH; Waxman S; Raggi P; Madjid M; Zarrabi A; Burke A; Yuan C; Fitzgerald PJ; Siscovick DS; de Korte CL; Aikawa M; Airaksinen KE; Assmann G; Becker CR; Chesebro JH; Farb A; Galis ZS; Jackson C; Jang IK; Koenig W; Lodder RA; March K; Demirovic J; Navab M; Priori SG; Rekhter MD; Bahr R; Grundy SM; Mehran R; Colombo A; Boerwinkle E; Ballantyne C; Insull W; Schwartz RS; Vogel R; Serruys PW; Hansson GK; Faxon DP; Kaul S; Drexler H; Greenland P; Muller JE; Virmani R; Ridker PM; Zipes DP; Shah PK; Willerson JT
    Circulation; 2003 Oct; 108(15):1772-8. PubMed ID: 14557340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of biomarkers for risk stratification of cardiovascular events using genetic algorithm with recursive local floating search.
    Zhou X; Wang H; Wang J; Wang Y; Hoehn G; Azok J; Brennan ML; Hazen SL; Li K; Chang SF; Wong ST
    Proteomics; 2009 Apr; 9(8):2286-94. PubMed ID: 19337989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive assessment of cardiovascular risk: from Framingham to the future.
    Vogel RA; Benitez RM
    Rev Cardiovasc Med; 2000; 1(1):34-42. PubMed ID: 12457150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
    Naghavi M; Libby P; Falk E; Casscells SW; Litovsky S; Rumberger J; Badimon JJ; Stefanadis C; Moreno P; Pasterkamp G; Fayad Z; Stone PH; Waxman S; Raggi P; Madjid M; Zarrabi A; Burke A; Yuan C; Fitzgerald PJ; Siscovick DS; de Korte CL; Aikawa M; Juhani Airaksinen KE; Assmann G; Becker CR; Chesebro JH; Farb A; Galis ZS; Jackson C; Jang IK; Koenig W; Lodder RA; March K; Demirovic J; Navab M; Priori SG; Rekhter MD; Bahr R; Grundy SM; Mehran R; Colombo A; Boerwinkle E; Ballantyne C; Insull W; Schwartz RS; Vogel R; Serruys PW; Hansson GK; Faxon DP; Kaul S; Drexler H; Greenland P; Muller JE; Virmani R; Ridker PM; Zipes DP; Shah PK; Willerson JT
    Circulation; 2003 Oct; 108(14):1664-72. PubMed ID: 14530185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment in the patient with established peripheral arterial disease.
    Haugen S; Casserly IP; Regensteiner JG; Hiatt WR
    Vasc Med; 2007 Nov; 12(4):343-50. PubMed ID: 18048472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice.
    Tabibiazar R; Wagner RA; Deng A; Tsao PS; Quertermous T
    Physiol Genomics; 2006 Apr; 25(2):194-202. PubMed ID: 16418319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of inflammation in atherosclerosis.
    Spagnoli LG; Bonanno E; Sangiorgi G; Mauriello A
    J Nucl Med; 2007 Nov; 48(11):1800-15. PubMed ID: 17942804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genesis and dynamics of atherosclerotic lesions: implications for early detection.
    Badimon JJ; Ibanez B; Cimmino G
    Cerebrovasc Dis; 2009; 27 Suppl 1():38-47. PubMed ID: 19342832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokines in cardiovascular risk prediction.
    Aukrust P; Yndestad A; Smith C; Ueland T; Gullestad L; Damås JK
    Thromb Haemost; 2007 May; 97(5):748-54. PubMed ID: 17479185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraplaque neovascularization and hemorrhage: markers for cardiovascular risk stratification and therapeutic monitoring.
    Koole D; Heyligers J; Moll FL; Pasterkamp G
    J Cardiovasc Med (Hagerstown); 2012 Oct; 13(10):635-9. PubMed ID: 22955205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.